Rasmus Kofoed will take over as Chief Executive Officer (CEO). He succeeds Lars Christian Lund, who after approximately 2 years in the role has decided to step down to take up a Group CEO position in another international company.

Rasmus Kofoed

Rasmus Kofoed brings a solid background in the life science and medtech industries. He has held senior leadership positions at Novo Nordisk, Abbott, Roche and Medtronic, and served as CEO of ChemoMetec, with overall commercial and strategic responsibility – including growth, transformation and international expansion. With this strong commercial experience, he will assume the role as CEO on 1 December 2025, with ambitions to further strengthen Hedia’s product and market platform and expand the company’s international partnerships.

“I see enormous potential in Hedia,” says Rasmus Kofoed. “The company combines clinical insight with technology in a way that creates real value for people with diabetes. I look forward to working with the team to extend our reach, strengthen our partnerships and continue the journey to make Hedia a leading player in digital diabetes care.”